Catalog No. F11-900
|Catalog No.||Pack Size||Price (USD)|
A potent and selective inhibitor of VEGFR2, ( KDR IC50 = 40 nM). Also inhibits fms-like tyrosine kinase 4 (VEGFR3, IC50 = 110 nM) and epidermal growth factor receptor (EGFR/HER1, IC50 = 500 nM) but shows selectivity against a panel of other tyrosine and serine-threonine kinases (1). Inhibits colony formation in seven cancer cell lines (2). Displays anti-angiogenesis activity (3).
1. SR Wedge et al. Cancer Res. 2002 62:4645
2. F Ciardiello et al. Clin. Cancer Res. 2003 9:1546
3. RS Herbst et al. Expert Opin. Investig. Drugs 2007 16:239
CAS Registry Number:
White to off-white powder
>98% (TLC); NMR (Conforms)
May be dissolved in DMSO (30 mg/ml); or ethanol (10 mg/ml, warm)
1. 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl) methoxy] quinazoline
Storage and Stability:
Store desiccated as supplied at -20oC for up to 2 years. Store solutions at -20oC for up to 1 month.
There are no related publications available for this product.
Angiogenesis, Cancer, Cell Cycle, Neurobiology